Imagin Medical Welcomes World-Renowned Bladder Cancer Expert Dr. Ashish M. Kamat to Its Scientific Board of Advisors
17 Abril 2019 - 9:00AM
Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart
Symbol: DPD2) (“Imagin” or the “Company”) today announced that Dr.
Ashish M. Kamat has joined its Scientific Advisory Board.
Dr. Kamat has been named by Expertscape as the
world’s top-rated expert in urinary bladder neoplasms. Dr. Kamat
has extensive experience with cystoscopic procedures, has been a
principal investigator for multiple oncology and urology clinical
studies for both drugs and devices, and has been involved in blue
light cystoscopy studies since 2007.
Dr. Kamat is an Endowed Professor of Urologic
Oncology and Cancer Research at University of Texas MD Anderson
Cancer Center (MDACC); Associate Cancer Center Director, RFHNH in
Mumbai, and President of International Bladder Cancer Group (IBCG)
and International Bladder Cancer Network (IBCN). He is Associate
Editor for European Urology Oncology, directed the MDACC Urologic
Oncology Fellowship from 2005-2016, and is an alumnus of the
American Urological Association Leadership Program.
Dr. Kamat received his medical degree at the
University of Bombay, India’s Seth G. S. Medical College & King
Edward Memorial Hospital and completed a fellowship in Urologic
Oncology at the MD Anderson Cancer Center. Dr. Kamat focuses on
bladder cancer, immunotherapy and organ sparing therapies. He
has led several national and international studies, which have been
reported in high impact journals. Dr. Kamat has over 300
publications, is listed in 'Who's Who in Medicine' and ‘Best
Doctors in America’, and has won the ‘Compassionate Doctor Award’
from patient groups.
“The advent of enhanced cystoscopy, especially
photodynamic diagnosis, has provided us with a means to better
detect, diagnose and treat our patients who have bladder cancer,”
said Dr. Kamat. “The technology being developed by the team at
Imagin has the potential to allow this technology to be adopted by
many centers which currently are not able to do so.”
“We are honored to have Dr. Kamat, a worldwide
bladder cancer expert, join our Scientific Advisory Board,” said
Jim Hutchens, Imagin’s President and CEO. “Dr. Kamat has extensive
experience with cystoscopy, so his expertise will be invaluable as
we progress the development of the Company’s i/Blue Imaging
System.”
“I am excited to join Imagin’s Scientific Board
of Advisors and look forward to supporting Imagin as it advances
i/Blue to commercialization,” said Dr. Kamat.
About Imagin Medical
Imagin Medical is a surgical imaging company
focused on establishing a new standard of care in visualizing
cancer during minimally invasive surgeries. The Company believes
its first product, the i/BlueTM Imaging System, will dramatically
improve surgeons’ ability to visualize cancerous cells by producing
higher-quality images more quickly compared with current methods.
Based on advanced optics and light sensors, the i/Blue Imaging
System employs patented ultrasensitive imaging technology and
offers easy-to-use viewing options for more accurate resection. The
Company’s initial focus is bladder cancer. Learn more at
www.imaginmedical.com.
Forward-Looking Statements
Information set forth in this news release
contains forward-looking statements. These statements reflect
management’s current estimates, beliefs, intentions and
expectations; they are not guarantees of future performance. The
Company cautions that all forward-looking statements are inherently
uncertain, and that actual performance may be affected by a number
of material factors, many of which are beyond the Company’s
control. Accordingly, actual and future events, conditions and
results may differ materially from the estimates, beliefs,
intentions and expectations expressed or implied in the
forward-looking information. Specifically, there is no assurance
the Company’s imaging system will work in the manner
expected. Except as required under applicable securities
legislation, the Company undertakes no obligation to publicly
update or revise forward-looking information. The CSE has neither
approved nor disapproved the information contained herein and does
not accept responsibility for the adequacy or accuracy of this news
release.
Contacts:
Stephen Kilmer, Investor Relations Telephone:
647-872-4849Email: stephen@kilmerlucas.com
Jim Hutchens, President & CEOTelephone:
833-246-2446
Imi Medical Innovations (AMEX:IME)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Imi Medical Innovations (AMEX:IME)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024